SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about press release

08 Mar 2023 Evaluate

Aurobindo Pharma has informed that it enclosed a copy of the Press Release that is being issued by the Company in connection with USFDA approval received by Eugia Pharma Specialities, a wholly owned subsidiary of the Company, for Lenalidomide Capsules.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1620.75 60.70 (3.89%)
03-Jul-2026 14:41 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.00
Dr. Reddys Labs. 1371.00
Cipla 1457.15
Zydus Lifesciences 1134.05
Lupin 2467.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: